心不全におけるSGLT2阻害剤の摂取を増やすためのデジタル導入戦略: EMAIL-HFの研究設計
Mariam Elmegaard1, Lars Køber2,3, Mads Kristian Ersbøll2
1Department of Cardiology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark.
ESC heart failure
|August 25, 2025
まとめ
デジタル戦略は,心臓機能不全 (HF) の患者のナトリウム-グルコース共輸送体2 (SGLT2) 阻害剤の開始を効果的に増加させ,加速させた. このアプローチは,通常のケアにおいて新しい治療法を実装するためのスケーラブルなモデルを提供します.
科学分野:
- 心臓病科
- デジタルヘルスの実施
- 薬剤療法
背景:
- 心不全 (HF) 管理ガイドラインは,ナトリウム・グルコース共輸送体2 (SGLT2) 阻害剤を推奨しています.
- ガイドラインに沿った治療の開始は,HF患者での治療結果の改善に不可欠です.
- 実施のギャップはしばしば新しい治療法を臨床実践で採用することを遅らせます.
研究 の 目的:
- HF患者におけるSGLT2阻害剤の発症の増加と加速におけるデジタルガイドラインの実施戦略の有効性を評価する.
- 新しいHF治療の採用を改善するためのスケーラブルなデジタルモデルの可能性を評価する.
主な方法:
- EMAIL- HF試験は実用的な,レジストリベースのランダム化制御試験です.
- SGLT2阻害剤を投与していない5996人の適格なHF患者は,デジタル介入または通常の治療を受けるために1:1でランダムに割り当てられました.
- 主なアウトカムは6ヶ月以内にSGLT2阻害剤の開始であり,二次的なアウトカムにはHF入院または全原因死亡が含まれていた.
主要な成果:
- この研究は,デジタル戦略がSGLT2阻害剤の吸収を改善できるかどうかを決定することを目的とした.
- 完全ベースラインの特徴と臨床結果は,イベントの発生後に報告されます.
- この試験には,デンマークで過去10年以内にHFと診断された患者が含まれていました.
結論:
- EMAIL-HF試験では,全集団にわたるデジタル戦略が慢性HFのSGLT2阻害剤の開始を促進するかどうかを確認します.
- この研究は,新しい治療法を日常的な臨床実践で実施するためのスケーラブルなモデルを提供することができる.
- この発見は,心臓血管医学におけるガイドラインの遵守を加速させるための戦略に役立つでしょう.
関連する概念動画
01:30Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
01:26Heart Failure Drugs: Inotropic Agents
717
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
717
01:22Heart Failure VI: Adjunct Therapies
27
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
27
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
01:22Heart Failure Drugs: Diuretics
483
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
483
01:30Heart Failure IV: Classification and Diagnostic Evaluation
32
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
32